Gemcitabine/Nab-Paclitaxel versus FOLFIRINOX in Locally Advanced Pancreatic Cancer: A European Multicenter Study

Gemcitabine/Nab-Paclitaxel versus FOLFIRINOX in Locally Advanced Pancreatic Cancer: A European Multicenter Study

Background: Gemcitabine/nab-paclitaxel (GN) and FOLFIRINOX (FFX) are two standard first-line therapies for metastatic pancreatic cancer (PC) but have rarely been compared, especially in patients with locally advanced PC (LAPC). Methods: This is a retrospective European multicenter study including pa...

Full description

Bibliographic Details
Main Authors: Nicolas Williet, Angelica Petrillo, Gaël Roth, Michele Ghidini, Mila Petrova, Julien Forestier, Anthony Lopez, Audrey Thoor, Lucie Weislinger, Ferdinando De Vita, Julien Taieb, Jean Marc Phelip
Format: Article
Language:English
Published: MDPI AG 2021-06-01
Series:Cancers
Subjects:
pancreatic cancer
FOLFIRINOX
gemcitabine/nab-paclitaxel
prognostic factors
predictors of response
Online Access:https://www.mdpi.com/2072-6694/13/11/2797

Internet

https://www.mdpi.com/2072-6694/13/11/2797

Similar Items